Dexcom, Inc.
$35.58B- Market cap
- $33.18B
- Debt
- +$3.32B
- Cash
- −$917.70M
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $33.18B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: DXCM stock price at premium vs BLK $87.92 current versus $66.43 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BLK's multiple
Implied fair value · at DXCM's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXCM FY 2025 (ended Dec 31, 2025) · BLK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Capital structure 93% equity / 7% debt · EV / Revenue 7.24x · EV / EBITDA 22.30x
BLK carries the larger enterprise value at $175.26B against $35.58B; BLK trades on the lower EV / Revenue multiple (7.24x vs 7.63x); BLK on the lower EV / EBITDA (22.30x vs 26.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BlackRock, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.21x
0.23x
Net debt / EBITDA
Leverage against operating earnings
1.81x
0.17x
Cash and equivalents
Liquid reserves on the balance sheet
$917.70M
$11.47B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DXCM vs ABT
Medtronic plc
DXCM vs MDT
BECTON DICKINSON & CO
DXCM vs BDX
STATE STREET CORP
DXCM vs STT
NORTHERN TRUST CORP
DXCM vs NTRS
PRICE T ROWE GROUP INC
DXCM vs TROW
The Goldman Sachs Group, Inc.
DXCM vs GS
Morgan Stanley
DXCM vs MS
Blackstone Inc.
DXCM vs BX
$3.32B
$12.77B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.